HLA class II neoantigen presentation for CD4+ T cell surveillance in HLA class II-negative colorectal cancer

Oncoimmunology. 2024 Dec 31;13(1):2404665. doi: 10.1080/2162402X.2024.2404665. Epub 2024 Sep 19.

Abstract

Neoantigen-reactive CD4+ T cells play a key role in the anti-tumor immune response. However, the majority of epithelial tumors are negative for HLA class II (HLA-II) surface expression, and less is known about the processing of HLA-II antigens. Here, we directly identified naturally presented HLA-II neoantigens in HLA-II negative colorectal cancer (CRC) tissue using a proteogenomic approach. The neoantigens were immunogenic and induced patient CD4+ T cells with a Th1-like memory phenotype that produced IFN-γ, IL2 and TNF-α. Multiplex immunohistochemistry (IHC) demonstrated an interaction between Th cells and HLA-II-positive antigen-presenting cells (APCs) at the invasive margin and within the tertiary lymphoid structures (TLS). In our CRC cohort, the density of stromal APCs was associated with HLA-II antigen presentation in the tumor microenvironment (TME), and the number of TLS was positively correlated with the number of somatic mutations in the tumors. These results demonstrate the presence of neoantigen-specific CD4+ surveillance in HLA-II-negative CRC and suggest a potential role for macrophages and dendritic cells (DCs) at the invasive margin and in TLS for antigen presentation. Stromal APCs in the TME can potentially be used as a source for HLA-II neoantigen identification.

Keywords: Antigen presentation; HLA class II; Th1 cells; neoantigen; tertiary lymphoid structures.

MeSH terms

  • Aged
  • Antigen Presentation* / immunology
  • Antigen-Presenting Cells / immunology
  • Antigens, Neoplasm / immunology
  • CD4-Positive T-Lymphocytes* / immunology
  • Colorectal Neoplasms* / immunology
  • Colorectal Neoplasms* / pathology
  • Dendritic Cells / immunology
  • Female
  • Histocompatibility Antigens Class II* / immunology
  • Humans
  • Male
  • Middle Aged
  • Tumor Microenvironment / immunology

Substances

  • Histocompatibility Antigens Class II
  • Antigens, Neoplasm

Grants and funding

This work was supported by the Japan Agency for Medical Research and Development (AMED) Grant to TK [24ama221315h0003], Japan Society for the Promotion of Science (JSPS) Grant to TK [24K02252], JSPS Grant to T. Tsujikawa [22K09688], AMED Grant to T. Tsujikawa [23zf0227002], JSPS Grant to ST [24K10110], and AMED Grant to T. Torigoe [24ama221328h0002]. This work was also supported by MEXT Promotion of Distinctive Joint Research Center Program [JPMXP0723833150].